IDIBELL and ICO researchers analise direct and indirect effects of the pandemic in haematological patients
The Clinical Research and Clinical Trials Unit renews its participation in the ISCIII Clinical Research Support Platform
The aid granted in the last competitive call for Clinical Research Support Platforms of the Carlos III Health Institute (ISCIII) almost triples that granted in the 2017 call, becoming one of the five best funded units of the 34 that make up the new ISCIII Platform throughout Spain.
A study led by IMIM-Hospital del Mar shows that, despite not participating in the programme, these people had lost an average of almost four kilos, two years after their family member started the programme
Researchers from IDIBELL and ICO establish a new classification of malignant mesothelioma that permits the prediction of the patient’s prognosis and determine those who could benefit from immunotherapy.
IDIBELL researchers identify three clinical profiles of patients with COVID-19 with prognostic implications
A study published in The Lancet Infectious Diseases, in which Bellvitge University Hospital (HUB) and the Bellvitge Biomedical Research Institute (IDIBELL) have participated, has identified three phenotypes (clinical profiles or forms of patient presentation) of COVID-19, each with a different mortality.
The consumption of sugary drinks, including fruit juices, is associated with an increased cancer risk
A new meta-analysis has analyzed the results of 67 observational studies published before June 2020 that confirms the association between a diet rich in sugary drinks and the increased development of breast, prostate, colorectal and pancreatic cancer.
A study of the IDIBELL and ICO team on infections and cancer, in collaboration with WHO and UNICEF, has analyzed the rate of vaccinations around the world. They found that, while there is still a long way and many challenges ahead, there are a few countries that have already achieved it. Therefore it is an acceptable goal.
Xavier Bosch: “If a person has doubts about whether they should be vaccinated, what we have to do is resolve these doubts”
We spoke with Dr. Xavier Bosch, principal investigator of the IDIBELL infection and cancer research group, doctor at the ICO, professor at the UOC, and expert in the vaccine against HPV (human papillomavirus), on the challenge of large-scale vaccination against COVID-19 and the reticence that this whole process is generating.